Harvard Bioscience, Inc.
HBIO
$7.08
$0.111.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 15.01% | -20.27% | -131.28% | 46.06% | 95.47% |
| Total Depreciation and Amortization | 1.85% | 0.00% | 1.96% | -18.07% | -2.36% |
| Total Amortization of Deferred Charges | 11.43% | -28.53% | 74.79% | 70.00% | 60.31% |
| Total Other Non-Cash Items | 116.86% | -89.85% | 392.73% | -18.48% | -99.12% |
| Change in Net Operating Assets | 24.69% | 186.49% | -416.55% | -89.60% | -20.59% |
| Cash from Operations | 149.09% | -589.58% | -108.86% | -60.65% | -7.74% |
| Capital Expenditure | -61.50% | 5.12% | -116.91% | -132.58% | 82.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -17.53% | -29.33% | -6.38% | 2.08% | 15.29% |
| Cash from Investing | -47.74% | -3.51% | -72.13% | -49.36% | 65.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -3,335.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -100.00% | 14,900.00% | -- | -100.00% | -- |
| Repurchase of Common Stock | -20.00% | 47.37% | -137.50% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 98.45% | 95.90% | -1,138.19% | 16.45% | -135.66% |
| Cash from Financing | -322.22% | -100.37% | 291.63% | -1.59% | -4.49% |
| Foreign Exchange rate Adjustments | 115.11% | -623.26% | 151.81% | -113.13% | 86.43% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 60.75% | -184.36% | 387.52% | -132.96% | 31.85% |